SCHEMBL8798676

SCHEMBL8798676

CC1CC(c2c[nH]c3cccc(O)c23)=CCN1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 7/20 0.40
HTR1A P08908 3/20 0.40
PDPK1 O15530 1/20 0.40
CCNT1 O60563 1/20 0.40
CCNB2 O95067 1/20 0.40
CDK1 P06493 1/20 0.40
CCNB1 P14635 1/20 0.40
PRKACA P17612 1/20 0.40
CCNA2 P20248 1/20 0.40
PRKACG P22612 1/20 0.40
PRKACB P22694 1/20 0.40
CDK2 P24941 1/20 0.40
GSK3B P49841 1/20 0.40
CDK9 P50750 1/20 0.40
CCNA1 P78396 1/20 0.40
CDK5 Q00535 1/20 0.40
SLC6A3 Q01959 1/20 0.40
CDK5R1 Q15078 1/20 0.40
CCNB3 Q8WWL7 1/20 0.40
HTR2A P28223 11/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7866364 0.75 HTR2C (0.61) HTR2BHTR1APDPK1CCNT1CCNB2
SCHEMBL6625901 0.73 HTR2C (0.41) HTR2BHTR1AHTR2AHTR2CHTR1D
SCHEMBL31357937 0.69 HTR2A (0.71) HTR2BHTR1APDPK1CCNT1CCNB2
SCHEMBL7866353 0.69 SLC6A4 (0.64) HTR1AHTR6KDM4EPOLBL3MBTL1
SCHEMBL30681636 0.69 SLC6A4 (0.64) HTR1AHTR6KDM4EPOLBL3MBTL1
SCHEMBL6497949 0.68 TDO2 (0.46)
SCHEMBL7205820 0.68 SLC6A4 (0.53) HTR1APDPK1CCNB2CDK1CCNB1
SCHEMBL9651757 0.65 HTR2C (0.56) HTR2BHTR1APDPK1CCNT1CCNB2
SCHEMBL29450053 0.65 HTR2C (0.56) HTR2BHTR1APDPK1CCNT1CCNB2
SCHEMBL4789469 0.64 ALDH1A1 (0.35) HTR2BHTR2AHTR2CGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250090554-A1 A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION MYND LIFE SCIENCES INC (CA) 2025-03-20 US disclosed
US-20240366638-A1 PSILOCYBIN ANALOGS FOR TREATING PSYCHOLOGICAL DISORDERS SYNAPTIVE THERAPEUTICS, LLC 2024-11-07 US disclosed
US-20230405026-A1 A Method of Treating Depression by Immune Modulation MYND LIFE SCIENCES INC (CA) 2023-12-21 US disclosed
EP-0812826-A1 1H-indole and benzo(b)thiophene derivatives with 4-(1,2,3,6-tetra:hydro:pyridinyl)- and 4-piperidinyl-groups bound to the heterocyclic ring as inhibitors of serotonin reuptake ELI LILLY AND COMPANY (US) 1997-12-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366638-A1 PSILOCYBIN ANALOGS FOR TREATING PSYCHOLOGICAL DISORDERS HTR1B, HTR2B, PNMT HTR2B 2/4885HTR1A 8/4885PDPK1 1661/4885
US-20230405026-A1 A Method of Treating Depression by Immune Modulation ABCF1, ABCF2, ABCB4 HTR2B 1193/4885HTR1A 507/4885PDPK1 1526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.